Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania. | Healthcare (Basel) | 2022 | 36292468 | PubTator, text mining | PubMed |
| TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study. | Curr Oncol | 2022 | 36290859 | PubTator, text mining | PubMed |
| The Role of Immunotherapy in Pancreatic Cancer. | Curr Oncol | 2022 | 36290818 | PubTator, text mining | PubMed |
| Application of Multigene Panels Testing for Hereditary Cancer Syndromes. | Biology (Basel) | 2022 | 36290365 | PubTator, text mining | PubMed |
| Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. | J Biomed Sci | 2022 | 36284291 | PubTator, text mining | PubMed |
| Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. | Cancer Control | 2022 | 36283420 | PubTator, text mining | PubMed |
| Effect of the PARP inhibitor veliparib on germ cell tumor cell lines. | Oncol Lett | 2022 | 36276487 | PubTator, text mining | PubMed |
| Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. | Front Immunol | 2022 | 36275669 | PubTator, text mining | PubMed |
| Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. | Gynecol Oncol | 2022 | 36273926 | PubTator, text mining | PubMed |
| PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. | Breast Cancer Res | 2022 | 36271417 | PubTator, text mining | PubMed |
| Association between XRCC3 p.Thr241Met polymorphism and risk of glioma: A systematic review and meta-analysis. | PLoS One | 2022 | 36264998 | PubTator, text mining | PubMed |
| Li-Fraumeni Syndrome: A Rare Genetic Disorder. | Cureus | 2022 | 36262946 | PubTator, text mining | PubMed |
| A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. | Nat Cancer | 2022 | 36253484 | PubTator, text mining | PubMed |
| DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. | Gynecol Oncol | 2022 | 36253303 | PubTator, text mining | PubMed |
| Gene-specific machine learning model to predict the pathogenicity of BRCA2 variants. | Front Genet | 2022 | 36246618 | PubTator, text mining | PubMed |
| Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway. | Int J Mol Sci | 2022 | 36233090 | PubTator, text mining | PubMed |
| Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing? | Int J Mol Sci | 2022 | 36232793 | PubTator, text mining | PubMed |
| Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study. | Int J Mol Sci | 2022 | 36232564 | PubTator, text mining | PubMed |
| Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. | Int J Environ Res Public Health | 2022 | 36231355 | PubTator, text mining | PubMed |
| PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. | Cancers (Basel) | 2022 | 36230674 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=42